In fungi, the anchoring of proteins to the plasma membrane via their covalent attachment to glycosylphosphatidylinositol (GPI) is essential and thus provides a valuable point of attack for the development of antifungal therapeutics. Unfortunately, studying the underlying biology of GPI-anchor synthesis is difficult, especially in medically relevant fungal pathogens because they are not genetically tractable. Compounding difficulties, many of the genes involved in coupling GPI to proteins are essential. Here, we report the discovery of a new drug-like small molecule christened gepinacin (for GPI acylation inhibitor) which selectively inhibits Gwt1, a critical acyltransferase required for the biosynthesis of fungal GPI anchors. After delineating the target specificity of gepinacin using genetic and biochemical techniques, we used it to probe key, therapeutically relevant consequences of disrupting GPI anchor metabolism in fungi. We found that unlike all three major classes of antifungals in current use, the direct antimicrobial activity of this compound results predominantly from overwhelming stress to the endoplasmic reticulum. Gepinacin did not affect the viability of mammalian cells or inhibit their orthologous acyltransferase, which enabled its use in co-culture experiments to examine its effects on host-pathogen interactions. In isolates of Candida albicans, the most common fungal pathogen in humans, exposure to gepinacin at sub-lethal concentrations impaired filamentation and unmasked cell wall β-glucan to stimulate a pro-inflammatory cytokine response in macrophages. These results highlight Gwt1 as a promising antifungal drug target and define a useful probe for studying how disrupting GPI-anchor synthesis impairs viability and alters host-pathogen interactions in genetically intractable fungi.
Abstract In fungi, the anchoring of proteins to the plasma membrane via their covalent attachment to glycosylphosphatidylinositol (GPI) is essential and thus provides a valuable point of attack for the development of antifungal therapeutics. Unfortunately, studying the underlying biology of GPI-anchor synthesis is difficult, especially in medically relevant fungal pathogens because they are not genetically tractable. Compounding difficulties, many of the genes involved in coupling GPI to proteins are essential. Here, we report the discovery of a new drug-like small molecule christened gepinacin (for GPI acylation inhibitor) which selectively inhibits Gwt1, a critical acyltransferase required for the biosynthesis of fungal GPI anchors. After delineating the target specificity of gepinacin using genetic and biochemical techniques, we used it to probe key, therapeutically relevant consequences of disrupting GPI anchor metabolism in fungi. We found that unlike all three major classes of antifungals in current use, the direct antimicrobial activity of this compound results predominantly from overwhelming stress to the endoplasmic reticulum. Gepinacin did not affect the viability of mammalian cells or inhibit their orthologous acyltransferase, which enabled its use in co-culture experiments to examine its effects on host-pathogen interactions. In isolates of Candida albicans, the most common fungal pathogen in humans, exposure to gepinacin at sub-lethal concentrations impaired filamentation and unmasked cell wall β-glucan to stimulate a pro-inflammatory cytokine response in macrophages. These results highlight Gwt1 as a promising antifungal drug target and define a useful probe for studying how disrupting GPI-anchor synthesis impairs viability and alters host-pathogen interactions in genetically intractable fungi. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48 Introduction Fungi are a prominent cause of hospital-acquired infections that are becoming increasingly difficult to control (1) . This disturbing trend is driven by the growing number of severely immunocompromised individuals in the population that has occurred as a result of advances in the management of cancer, organ transplantation, autoimmune disorders and HIV. Most fungus-related morbidity and mortality is caused by the pathogens Candida albicans and Aspergillus fumigatus, which remain costly to treat and extremely difficult to eradicate in the immunocompromised host. Candida species are currently the fourth leading cause of hospital-acquired bloodstream infection and kill up to 40% of their victims, while disseminated Aspergillus infections kill up to 80% of the patients they afflict (2, 3) .
Fungal pathogens present a particular therapeutic challenge because as eukaryotes, they share many of the same basic molecular mechanisms that support the maintenance and proliferation of mammalian cells. As a consequence, the number of unique exploitable drug targets that have been identified in fungi remains very limited. Only three mechanistically distinct classes of anti-mycotic agents are in widespread clinical use for the treatment of systemic infections. The most widely deployed class, the azoles (e.g. fluconazole), inhibit the cytochrome P450 enzyme 14 α-demethylase. This blocks the conversion of lanosterol to ergosterol, the functional homolog of cholesterol in mammals.
Ergosterol is an essential component of the fungal membrane and the selective fungistatic activity of the azoles results from their disruption of its biosynthesis. Ergosterol itself is the primary target of the oldest class of antifungals, the polyenes (e.g. amphotericin B) which selectively bind this sterol and directly disrupt fungal membrane integrity. The newest class of antifungals, the echinochandins (e. g. caspofungin), inhibits 1, 3 β-glucan synthase. This enzyme mediates an essential step in the production of glucan, the major structural component of the fungal cell wall. Unfortunately, high-grade resistance to 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 all three classes of antifungals occurs frequently in the clinical setting through molecular mechanisms that can involve both target-related mutations and increased transporter-mediated drug efflux. Clearly, to combat this mounting medical problem, effective new anti-fungal strategies are urgently needed.
Motivated by a long-standing interest in the basic biology of stress responses and how they enable diverse organisms to adapt and evolve, we identified a novel chemical structure that induces profound stress in the endoplasmic reticulum (ER) of fungi. Intrigued by its high fungal-selective activity against a broad range of medically relevant species, we sought to define its mechanism(s) of action through a combination of genetic and biochemical approaches. We found that this drug-like compound, which we here name gepinacin, specifically inhibits an essential step in the production of glycosylphosphatidylinositol (GPI)-anchors within the ER of fungi, but not mammalian cells. Guided by this insight, we used the compound as a probe to investigate how inhibiting this biosynthetic pathway disrupts protein homeostasis in fungi and alters key interactions between pathogen and host that are known to contribute to fungal virulence.
RESULTS AND DISCUSSION
In the course of high-throughput screening for small molecules that inhibit the function of heatshock proteins, we encountered a false positive compound that possessed surprisingly broad anti-fungal activity. Under screening conditions, the compound caused swelling of the yeast, Saccharomyces cerevisiae, which caused it to score erroneously in a cell growth assay. Closer examination revealed that the compound was actually toxic to yeast. In contrast, no growth inhibition was seen when the compound was incubated with mammalian cells in culture. Intrigued by its marked fungal selectivity, we took advantage of the powerful genetic tools developed in the model fungal organism S. cerevisiae to identify the target of this small molecule and to understand the basis of its selective toxicity to fungi.
Following target validation, we used this compound as a chemical probe to further characterize its mode 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 of action and explore the therapeutic implications of target inhibition in azole-resistant isolates of the far less genetically tractable but more medically relevant fungal pathogen, C. albicans.
Broad spectrum of highly selective antifungal activity
The phenoxyacetanilide compound identified in our screen ( Fig. 1a) inhibited the growth of diverse yeasts and molds separated by approximately 800 million years of evolution, including S. cerevisiae, Candida glabrata, Candida albicans and Aspergillus terreus (4). This suggested the involvement of a mechanism widely conserved amongst fungi ( Fig. 1b) . Importantly, it inhibited the growth of multiple isolates of the common fungal pathogen C. albicans. These had been chosen to represent resistance to each of the three major classes of antifungals that are currently in clinical use ( Fig. 1c) . The lack of cross-resistance and the absence of structural similarity to established antifungal drugs suggested the compound might exert its activity through a novel mode of action. A complete lack of cytotoxicity for mammalian cells suggested sufficient divergence of target and/or mechanism between humans and fungi to provide a useful therapeutic index for eventual development of the chemotype as an antimicrobial ( Fig. 1d ).
Target Identification Using Yeast Genetics
To determine the mechanism responsible for the antifungal activity of the compound, we utilized the powerful genetic tools available in the model fungal organism S. cerevisiae. We screened both an arrayed haploid over-expression library and a pooled heterozygous deletion library for enhancement or suppression of toxicity. The over-expression library consisted of 5336 individual haploid strains arrayed in 384-well plate format. With each strain expressing one open reading frame (ORFs), this library covered approximately 90% of the yeast genome. (5) . Our heterozygous deletion library consisted of a pool of 5797 diploid strains in which one copy of approximately 95% of the ORFs in the S. cerevisiae genome had been disrupted previously by targeted insertion of a bar-coded antibiotic resistance cassette 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58 59 60 (6) . Only one gene, GWT1 was recovered as a hit shared by both libraries. Gwt1 is essential for growth of S. cerevisiae under normal conditions and has previously been characterized as an acyltransferase that is critical for GPI-anchor biosynthesis (7) . Having identified this putative target for the compound we christened the compound gepinacin for GPI acylation inhibitor. When GWT1 was over-expressed, it rescued gepinacin toxicity and when it was deleted, toxicity was enhanced. Furthermore, GWT1 was not identified as a hit for 8 unrelated compounds that were tested in parallel for other projects. To confirm the effect of GWT1 we constructed yeast strains engineered to express a wide range of GWT1 gene copies ( Fig. 2a) . Starting with a wild type diploid (Wt) strain that carries two genomic copies of GWT1, we introduced a low copy (CEN) plasmid expressing GWT1 or GFP (as a control). In parallel, the same plasmids were transduced into a heterozygous deletion strain (gwt1∆/GWT1) which had only one genomic copy of GWT1. As expected, the toxicity of gepinacin inversely correlated with GWT1 copy number. High level expression of GWT1 driven by a two micron plasmid further decreased gepinacin activity in both genotypes ( Supplementary Fig. 1 ). These genetic data establish Gwt1, or at least the pathway in which it acts, as the most functionally relevant target for the antifungal activity of gepinacin.
Biochemical validation of Gwt1 as target
Production of GPI-anchors begins on the cytoplasmic surface of the ER but is completed on the luminal side. Gwt1 (in yeast) or PIG-W (mammalian) acts at the first step on the luminal side of the ER, the acylation of glucosamine phosphatidylinositol (GlcN-PI) ( Fig. 2b) (8) (9) . To provide direct biochemical evidence that Gwt1 is the proximal protein target of gepinacin we performed in vitro acylation reactions using yeast membrane preparations. UDP[ 3 H]GlcNAc was incubated with the membranes, the resulting lipid products were recovered by chemical extraction and fractionated by silica gel thin layer chromatography (TLC). The appearance of a phospholipase-C insensitive band indicated the production of the acylated product. Gepinacin inhibited the acylation of GlcN-PI at low micromolar concentration ( Fig. 2c ) while a compound that was structurally very similar but biologically inactive did not ( Fig. 1a, Supplementary Fig. 2 ).
Having demonstrated that the biochemical target of gepinacin is not restricted to fungi, we were interested in investigating the basis of its lack of toxicity to mammalian cells in culture. To determine if gepinacin remained active under mammalian cell culture conditions we cultured fungi (either an amphotericin B-resistant ( Fig. 3a) or fluconazole-resistant (data not shown) isolate of C. albicans) and mammalian cells together. These co-culture experiments demonstrated profound inhibition of proliferation for both fungal strains under serum-containing cell culture conditions, with no effect on mammalian cells in the same well.
To determine whether the basis of fungal selectivity resided in the fungal protein itself, we constructed transgenic S. cerevisiae strains in which genomic deletion of the essential GWT1 gene was rescued by heterologous expression of either the human or yeast genes (PIG-W or GWT1, respectively) thus confirming the highly conserved function of Gwt1/PIG-W. While gepinacin was inactive in the PIG-W expressing strain, it potently inhibited both cell growth and acyltransferase activity in the strain expressing the yeast gene ( Fig. 3b, 3c) . These results confirm the proximal determinant of gepinacin toxicity as the fungal Gwt1 protein and demonstrate highly species-selective activity for the compound.
Deletion of Trafficking Adaptor Protein EMP24 Partially Suppresses Toxicity
To identify mechanisms that might confer resistance we isolated two spontaneously arising gepinacin-resistant clones carrying mutations that partially suppressed gepinacin toxicity in S cerevisiae ( Fig. 4a) . Whole genome sequencing of these strains showed that resistance was due to two different mutations in the gene EMP24 (Fig. 4b) . This finding was recapitulated with targeted deletion of EMP24 ( Supplementary Figure 3 ). The non-essential protein Emp24 is a component of a large multi-protein complex that regulates GPI-anchored protein transport and quality control (10) . GPI-anchored proteins do not contain transmembrane domains. As an integral membrane protein, Emp24 specifically interacts with the anchor portion of GPI-anchored proteins monitoring the completion of their processing and assisting their incorporation into ER to Golgi transport vesicles (11) . When GPI-anchored proteins are incompletely remodeled, Emp24 is thought to facilitate their return to the ER. The deletion or inactivation of EMP24 has been shown to allow GPI-anchored proteins to bypass this quality control step and to exit the ER (11) . Deletion of EMP24 could suppress gepinacin toxicity in an analogous manner by relieving a trafficking block induced by the compound.
To determine if gepinacin does indeed alter trafficking and change Emp24 distribution we examined yeast in which GFP was fused in frame to the 3' end of genomic EMP24. Emp24-GFP normally shows a classical ER distribution pattern consisting of well-defined circles in the interior of the cell with a fainter cortical ring and a few bright dots consistent with some Golgi localization. After overnight culture in gepinacin, however, Emp24-GFP dramatically re-localized into large, bright dotlike structures (Fig. 4c) . This pattern indicates that the compound had induced severe disorganization of the ER, and/or a profound block in retrograde trafficking that would normally return Emp24 to the ER as part of its physiological cycling.
GPI-specific trafficking defects caused by gepinacin induce ER stress
To further pursue the effects of gepinacin on protein trafficking in the secretory compartment, we compared the effects of gepinacin on maturation of the sentinel proteins Gas1 and CPY. Both proteins undergo characteristic molecular weight changes as they are processed in transit through specific cellular compartments, a feature that has been used extensively to study protein trafficking in the secretory system. Gas1 travels through the ER where it acquires a GPI-anchor before translocating 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 to the Golgi and outward to the cell surface (12) . CPY is not GPI-anchored but undergoes sorting and processing in the secretory pathway before ending up in the yeast vacuole (13) . In actively growing wild type yeast, the mature (m), Golgi-processed form of Gas1 constitutes the predominant species, relative to the precursor (p) form found in the ER (Fig. 5a) . This distribution was inverted following exposure to gepinacin. In contrast, the processing of CPY which is not GPI-anchored was identical in control and gepinacin-treated cells. This confirms a highly restricted effect of Gwt1 inhibition on the trafficking of GPI-anchored proteins. The control compound, tunicamycin, a natural product that blocks production of all N-linked glycoproteins, alters the processing of both proteins as expected (14) .
The specific effects of gepinacin on GPI-anchored proteins provided a highly selective tool to investigate the impact of inhibition of inositol acylation on protein homeostasis within the ER. Culture for 5 hours in gepinacin induced a massive, concentration-dependent activation of the unfolded protein response (UPR) as monitored by the GFP reporter construct (UPRE-GFP), similar in extent to the effect produced by tunicamycin ( Fig. 5b) . Activation of the UPR was not seen when yeast were treated with representative compounds from the three major classes of anti-fungals: amphotericin B, caspofungin and fluconazole ( Supplementary Figure 4) . As expected based on its target selectivity, gepinacin did not perturb ER function in mammalian cells as monitored by induction of BIP, an ER-resident chaperone and classical marker of the UPR in mammalian cells (Supplementary Figure 5 ) (15, 16) . Deletions of HAC1 and IRE1 which are essential components of the UPR activation pathway in yeast, both greatly increased the toxicity of gepinacin ( Fig. 5c) . As a positive control, similar enhancement of tunicamycin toxicity was seen in association with deletion of these genes (Supplementary Figure 6a) . In contrast, toxicity of the conventional antifungal fluconazole which targets ergosterol biosynthesis was completely unaffected by these UPR-disabling deletions (Supplementary Figure 6b ) (17). 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 Gwt1 Inhibition Blocks Filamentation GPI-anchoring of proteins is conserved in all eukaryotes. However, major differences in the utilization of this post-translational modification between species provide an attractive point of attack in developing new antimycotics. In fungi, unlike mammalian cells, GPI-anchored proteins become covalently linked to β-1, 6 glucan following translocation to the cell surface which helps maintain integrity of the cell wall. In addition, their presence at the cell surface permits GPI-anchored proteins in fungi to play important roles in adhesion, filamentation and sensing of the environment. Also important to pathogenesis, they provide a heavily glycosylated and phosphorylated outer coat to shield fungi from recognition and attack by the immune system of the mammalian hosts they invade (18, 19) .
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Because of its role in tissue invasion, a key determinant of fungal virulence is the ability to switch between yeast and filamentous forms (20-22). To determine whether gepinacin impairs this important process in C. albicans, we used a series of three increasingly fluconazole-resistant clinical isolates that had been isolated over a two year period from an HIV patient treated with fluconazole, strains CaCi2, 8 and 17 (23). These strains were grown overnight with gepinacin or vehicle control in rich medium at 30° C, to maintain the cells in the yeast form. To induce morphogenic transformation they were then transferred to filamentation medium (Spider medium) at 37°C for 3 hours in the continued presence or absence of gepinacin (24). In the absence of gepinacin, all three drug-resistant clinical isolates underwent marked transformation to large macroscopic mats, readily visible to the eye.
Because this process is so dependent on GPI-anchored proteins, however, a concentration of gepinacin that minimally reduced proliferation completely blocked the ability of all three strains to undergo such filamentation (Fig. 6a) . The inability to form filaments was also apparent at the cellular level as demonstrated by the photomicrographs provided in Supplementary Figure 7 . Comparable results were obtained when using serum-containing medium to induce filamentation instead of "Spider medium". 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 Gepinacin also blocked filamentation on solid media using the well-characterized S. cerevisiae strain Sigma 1278B, which spontaneously grows as filamentous mats on agar substrates (Fig. 6b) . Clearly the ability of gepinacin to inhibit conversion of fungi to their invasive filamentous forms is broadly relevant to diverse species and growth conditions with important implications for their pathogenicity in animal hosts.
Gwt1 inhibition enhances immunogenicity
We took advantage of the fungal selectivity of gepinacin to investigate another key determinant of fungal virulence, namely the ability to escape immune recognition. The large amount of β-glucan in the cell wall of fungi constitutes a potent pro-inflammatory stimulus, but it is normally masked by a mannoprotein coat (25). We predicted that disrupting GPI-anchor synthesis through inhibition of Gwt1 would unmask β-glucan leading to enhanced recognition of Candida by mammalian immune cells.
Indeed, as revealed by immunostaining and fluorescence microscopy, sub-lethal concentrations of gepinacin did dramatically increase β-glucan presentation on the cell surface of C. albicans (Fig. 7a) .
Quantitation of this effect by flow cytometry confirmed a 4.5-fold increase in median channel fluorescence for gepinacin-treated candida compared to control-treated yeast. Such β-glucan exposure has been demonstrated previously for caspofungin, an echinochandin that perturbs cell wall synthesis. In contrast to gepinacin, however, the effect of caspofungin is limited to only filamentous forms of C. albicans (26). As an important functional consequence of increased β-glucan exposure, incubation of gepinacin-treated C. albicans with a mouse macrophage cell line (RAW264.7) more than doubled the secretion of the major pro-inflammatory cytokine TNFα by these professional antigen-presenting cells ( Fig. 7b) . 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 Gwt1 as a target for antifungal drugs
The biosynthesis of GPI anchors in fungi was first proposed as a potential antifungal drug target by Tsukahara et al (27) . In an extensive screening effort, they identified 1-[4-butylbenzyl] isoquinoline (BIQ) as an inhibitor of the surface expression of GPI-anchored proteins (structure in Supplementary   Figure 8a) . GWT1 was subsequently cloned as a dosage-dependent suppressor of BIQ-induced phenotypes. Further discovery and optimization efforts by this group led to the synthesis of E1210, a potent and selective Gwt1 inhibitor with properties suitable for clinical development (structure in Supplementary Figure 8b) . E1210 shows good activity in vitro and in mouse models against a broad spectrum of yeast and molds including medically relevant species of candida, aspergillus and fusarium (28, 29). Like gepinacin, it is non-toxic to mammalian cells at concentrations that far exceed those required for antifungal activity (30). The unusually high degree of selectivity for both gepinacin and E1210 arises from species-specific discrimination at the biochemical level of target inhibition and from the different roles that GPI-anchored proteins play at the biological level in fungi versus mammals.
Although the structurally distinct compounds gepinacin and E1210 were discovered through completely different screening strategies, they share key biological properties rooted in Gwt1, the molecular target they hold in common. Both compounds inhibit fungal proliferation, compromise cell wall integrity and impair the morphogenic filamentation program which is required for pathogenicity in animal hosts (30). Our discovery of a new chemotype that selectively inhibits the fungal protein Gwt1 highlights the suitability of this protein as a highly druggable, therapeutic target. This is noteworthy from the drug development perspective because Gwt1 and its close mammalian ortholog are multi-pass transmembrane proteins for which atomic-level structural information is not available to help guide medicinal chemistry efforts. In pursuing the work presented here, we have constructed gene-swapped yeast strains in which the sole source of essential acyltransferase activity for GPI anchor synthesis is 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 provided by either Gwt1 or its human ortholog PIG-W. These strains can now be used for SAR studies to optimize the potency and selectivity of the known chemotypes and also to efficiently screen for yet other compounds that preferentially inhibit the fungal enzyme or alternatively that inhibit the human enzyme to study its role in mammalian biology (9) .
Using gepinacin as a probe in medically relevant pathogens for which few genetic tools are available, we have uncovered new consequences of Gwt1 inhibition with important clinical implications. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 The reporter for the unfolded protein response, pRS304-4XUPRE-GFP, was a gift from Peter Walter (UCSD).
Fungal Strains.
Archives of all strains were maintained in 25% glycerol at -80°C. A complete list of all strains and construction details for the humanized yeast strain are provided in the supplement.
Mammalian Cell Lines. 293T, NIH 3T3, and the RAW264.7 murine macrophage line were purchased from ATCC. Primary MEF were generated from day 13.5 mouse embryos using standard techniques.
Antifungal Susceptibility Testing. Sensitivity to gepinacin was determined in 96-well, flat bottom microtiter plates using a modification of the broth microdilution protocol NCCLS M27-a and RPMI as culture medium. Fungi were inoculated at ~ 10 3 cells per ml and incubated for 48 hours at 37° C after which plates were sealed, shaken and the optical density read at 600 nm (OD 600 ) on a Tecan Safire 2 plate reader. All samples were run in duplicate or triplicate and assays were repeated at least once.
Results are expressed as fraction of growth in the absence of compound and the mean and standard deviation are plotted. For the mold A. terreus, inoculum was 10 4 cells per ml and plates were incubated at 35° C for 48 hours in the dark. Plates were then visually scored as specified by CLSI document M38-A2 to determine the MIC50 and MIC80.
Mammalian Cell Toxicity Testing. For co-culture experiments, confluent layers of NIH 3T3 cells
were established in 6-well plates. The following day, the medium was replaced with RPMI1640+10%FBS containing the amphotericin-resistant strain CaAmphR at 10 3 colony forming units per ml and 40 µM Gepinacin or an equivalent amount of DMSO. Co-cultures were incubated for 24 hours at 37° C in a micro-isolator box. Images were acquired on a Nikon Eclipse TS100 microscope at 40X.
Genetic Screening. Flexgene plasmids were transformed in parallel into S. cerevisiae strain BY4741.
The resulting library was arrayed in 384-well plates, grown to saturation in selective media, diluted and 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 replicated using a Tecan EVO robot. Gepinacin (20 µM) or an equivalent amount of DMSO in SGal-URA-NH4 media was added to duplicate plates before incubation in a humidified chamber at 23°C in the dark. Plates were sealed, shaken, and read at 24 hours and then 4 more times over the next 2 days.
Data analysis details are provided in the supplement. The heterozygous deletion collection was pooled and grown at 30° C in SGal-CSM with shaking to an OD 600 of approximately 1-2 and then diluted to an OD 600 of 0.05 in fresh media containing DMSO or 1.25 µM gepinacin. This was repeated 4 times with dilutions every ~ 12 hours. Genomic DNA preparation, PCR and chip hybridization were done as previously described (6, 32, 33) . All hits were re-tested by growth assay in 384-well plate format and the relevant deletion confirmed by PCR with deletion specific primers.
In vitro Acylation Assays. Experiments were performed using a previously published protocol (7) Filamentation. For liquid assays, C. albicans strains were grown overnight in YPD with DMSO or 5 µM gepinacin. After dilution to an OD 600 of 0.1 in Spider media, growth was continued for an additional 3 hours with agitation at 37°C in the presence of compound before transfer to a 24 well plate for imaging (34) . Assays with S. cerevisiae strain Sigma 1278B on solid media were performed as previously described (24) except gepinacin was added directly to partially cooled plate media and colonies were imaged after growth for 6 or 9 days at 30° C.
Protein trafficking analysis. HA-tagged GAS1 was expressed in strain BY4741 CPY-GFP (Yeast GFP collection (35) under control of its own promoter using plasmid pCM-HA-GAS1. This construct was created as previously reported except in a gateway plasmid backbone (36) . To assess effects on trafficking, 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 strains were incubated for 1 hour at 30°C with test compounds. Total cellular protein (5 µg) was separated by electrophoresis (Invitrogen 8% gels) and transferred to nitrocellulose membranes. Blots were hybridized with antibodies against HA (Covance), GFP (Roche) or CPY (Invitrogen). Sizes for the various post-translationally modified products of Gas1HA2 and CPY have been previously reported (36) . CPY-GFP was used to facilitate discrimination of CPY processing steps because GFP is cleaved from CPY in the yeast vacuole. The experiment, however, was also performed with untagged CPY with the same results.
Unfolded protein response. The plasmid pRS304-4XUPRE-GFP was linearized and integrated into the TRP1 locus of S. cerevisiae (W303) to construct a reporter strain as previously described (37, 38) .
Reporter cells were grown to log phase and exposed to compound at 23° C for 5 hours before analysis.
GFP reporter induction was monitored on a Guava EasyCyte Plus cytometer. The average mean channel fluorescence of duplicate samples was determined and the experiment was performed twice with similar results. β-glucan staining. Overnight treatment and staining of C. albicans strain Sc5314 was performed as previously described for caspofungin treatment using YPD media at 30° C to maintain growth in the yeast form (39) . Antibody to (1-3) β-D-glucan was obtained from Biosupplies (Australia). Cells were propidium iodide (PI) stained to assess viability and only PI -negative cells were analyzed. Microscopy was performed on a Nikon Eclipse microscope with a 100X oil objective. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 harvested and TNFα concentration measured by ELISA using a kit according to manufacturer's instructions (DY410, R&D Systems).
Macrophage stimulation and
Suppressor strains.
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Material and Methods
Fungal strains. Standard S. cerevisiae lab strains W303, BY4741, BY4742 and BY4743 were used for experiments. The C. albicans wild type strain in Figure 1 was CaI4, a standard laboratory strain (1). The Humanized yeast strain. Because GWT1 deletion is lethal in S. cerevisiae strain BY4741, a haploid shuttle strain was constructed in which the genomic copy of GWT1 was deleted and replaced by GWT1 on a plasmid that also encoded the URA3 gene and a G418-resistance gene. To construct this shuttle strain a gwt1/GWT1 heterozygous deletion mutant was transformed with pAGGPD416-GWT1, sporulated and dissected. A colony was selected that grew on both SD-URA and G418-containing plates. PCR with the deletion specific primers (http://wwwsequence.stanford.edu/group/yeast_deletion_project/deletions3.html) was performed to confirm the GWT1 deletion. To change the source of GWT, this shuttle strain was transformed with plasmids containing GWT1 (as a control) or PIG-W and the LEU2 auxotrophy gene followed by selection for growth on SD-LEU plates. Plasmids were constructed by conventional Gateway technology using a
GWT1encoding entry vector and either pAG415GPDccdB or pAG425GPDccdB as the destination vectors. Positive colonies were selected and grown on 5-Fluoroorotic acid (5-FOA)-containing plates to promote loss of the pAGGPD416-GWT1 plasmid. The colonies from this plate were then tested for return of uridine auxotrophy to confirm pAGGPD416-GWT1 loss. The PIG-W expression vector was constructed by recombination in yeast as follows. The pAG415GPDccdB vector was cut with Xho1 and Xba1 and the larger piece was gel and column purified. The coding sequence of PIG-W was PCR amplified from the entry clone so that it would have ends facilitating recombination with the cut vector.
The shuttle strain was then transformed with these two DNA fragments and plated on SD-LEU plates to select for recombinants. PIG-W plasmid was isolated from the final strain and sequence verified. Analysis of sequencing data-After quality control was performed on raw reads for each genome, we aligned the filtered reads against the S. cerevisiae reference sequence sacCer2, (June 2008 assembly, downloaded from UCSC on April 1, 2011:
http://hgdownload.cse.ucsc.edu/goldenPath/sacCer2/chromosomes/) using the BWA aligner (7) . For each of the strains, we called SNPs and indels with respect to the reference using mpileup from the SAMtools package (8) . To identify SNPs and indels unique to each of the resistant strains, we compared the parental strain to individual resistant lines. We used a combination of custom code and the Genome Analysis Toolkit (GATK) (9) to locate, and then rank by quality, the SNPs and indels detected in open reading frames that were present only in the suppressor strains. Alignments of the reads for the top ranked SNPs and indels were then visually inspected.
Supplementary Figure Legends
Supplementary Figure 1 GWT1 copy number determines gepinacin sensitivity. Anti-fungal susceptibility testing of wild type diploids (Wt) or diploids with one copy of GWT1 deleted (gwt1/GWT1) transformed with high copy (2 micron) plasmids containing GWT1 or GFP (as a control). The strains were treated with gepinacin for 48 hours and the growth was monitored by measuring the optical density at 600 nm (OD 600 ). The results are expressed as a fraction of the OD 600 measured in the absence of gepinacin.
Supplementary Figure 2
A close structural analog of gepinacin does not inhibit growth. Anti-fungal susceptibility testing of a fluconazole-resistant C. albicans strain under standard conditions. Yeast were incubated at 30° C for 24 hours with serial dilutions of the indicated compounds. Growth was monitored by OD 600 and is expressed as fraction of the growth observed in the absence of compound.
Supplementary Figure 3
EMP24 deletion partially suppresses inhibition of growth by gepinacin. Anti-fungal susceptibility testing of S. cerevisiae strains that are wild type or deleted for EMP24. Growth was assessed by measuring the OD 600 following gepinacin treatment for 48 hours at 30° C in 96-well plate format. Mean and standard deviation of triplicate determinations are shown.
Supplementary Figure 4
Conventional anti-fungal drugs do not induce the UPR. Induction of the unfolded protein response in cells carrying a GFP reporter construct was monitored by flow cytometry after exposure to serial dilutions of the indicated compounds for 5 hrs. Strong induction by gepinacin and tunicamycin but not by conventional anti-fungal drugs is evident.
Supplementary Figure 5
BIP level, an indicator of the UPR in mammalian cells, is not increased after gepinacin treatment.
Immunoblot of lysates prepared from human leukemia cells (K562) using an antibody to BIP after 28 hour exposure to tunicamycin (1 g ml -1 ), gepinacin (20 M) or solvent vehicle (DMSO, 0.1%). Betaactin was blotted as a loading control.
Supplementary Figure 6
Compromising the UPR enhances tunicamycin toxicity but does not alter the toxicity of fluconazole.
Anti-fungal susceptibility testing of strains bearing deletion of IRE1 (activator of the UPR) or HAC1
(effector of the UPR) using either tunicamycin (A) or fluconazole (B). Growth was measured by OD 600 after 48 hour exposure to serial dilutions of the compounds as indicated. Results are expressed as a fraction of the OD 600 measured in the absence of gepinacin.
The mean and standard deviation of triplicate determinations are shown.
Supplementary Figure 7
Gepinacin blocks morphogenic switching in C. albicans. Three drug-resistant strains of C. albicans were treated with DMSO or gepinacin (5 µM) and induced to filament for 3 hours. DIC images were acquired at 60X. 
